Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis

Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis

Background/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, Clinical...

Full description

Bibliographic Details
Main Authors: Mingyi Zhou, Ping Yu, Jinglei Qu, Ying Chen, Yang Zhou, Lingyu Fu, Jingdong Zhang
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2016-11-01
Series:Cellular Physiology and Biochemistry
Subjects:
RAS mutations
Network meta-analysis
Metastatic colorectal cancer
First line treatment
Online Access:http://www.karger.com/Article/FullText/452551

Internet

http://www.karger.com/Article/FullText/452551

Similar Items